The intriguing role of soluble urokinase receptor in inflammatory diseases

References

• Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010;11:23–36
   PubMed Web of Science ®Google Scholar
• Enocsson H, Sjöwall C, Wetterö J. Soluble urokinase plasminogen activator receptor-a valuable biomarker in systemic lupus erythematosus? Clin Chim Acta 2015;444:234–41
   PubMed Web of Science ®Google Scholar
• Haupt TH, Kallemose T, Ladelund S, et al. Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population. Biomark Insights 2014;9:91–100
   PubMedGoogle Scholar
• Rasmussen LJ, Ladelund S, Haupt TH, et al. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study. Emerg Med J 2016. [Epub ahead of print]. doi:10.1136/emermed-2015-205444
   PubMed Web of Science ®Google Scholar
• Haupt TH, Petersen J, Ellekilde G, et al. Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study. Crit Care 2012;16:R130
   PubMed Web of Science ®Google Scholar
• Raggam RB, Wagner J, Prüller F, et al. Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome. J Intern Med 2014;276:651–8
   PubMed Web of Science ®Google Scholar
• Koch A, Zimmermann HW, Gassler N, et al. Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure. Liver Int 2014;34:1330–9
   PubMed Web of Science ®Google Scholar
• Donadello K, Scolletta S, Taccone FS, et al. Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients. J Crit Care 2014;29:144–9
   PubMed Web of Science ®Google Scholar
• Nielsen LS, Kellerman GM, Behrendt N, et al. A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J Biol Chem 1988;263:2358–63
   PubMed Web of Science ®Google Scholar
• Sidenius N, Sier CF, Blasi F. Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett 2000;475:52–6
   PubMed Web of Science ®Google Scholar
• Huang M, Mazar AP, Parry G, et al. Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143). Acta Crystallogr D Biol Crystallogr 2005;61:697–700
   PubMedGoogle Scholar
• Hoyer-Hansen G, Lund IK. Urokinase receptor variants in tissue and body fluids. Adv Clin Chem 2007;44:65–102
   PubMed Web of Science ®Google Scholar
• Furlan F, Orlando S, Laudanna C, et al. The soluble D2D3(88-274) fragment of the urokinase receptor inhibits monocyte chemotaxis and integrin-dependent cell adhesion. J Cell Sci 2004;117:2909–16
   PubMed Web of Science ®Google Scholar
• Higazi AA, Mazar A, Wang J, et al. Soluble human urokinase receptor is composed of two active units. J Biol Chem 1997;272:5348–53
   PubMed Web of Science ®Google Scholar
• Behrendt N, Ronne E, Dano K. Domain interplay in the urokinase receptor. Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains. J Biol Chem 1996;271:22885–94
   PubMed Web of Science ®Google Scholar
• Trigwell S, Wood L, Jones P. Soluble urokinase receptor promotes cell adhesion and requires tyrosine-92 for activation of p56/59(hck). Biochem Biophys Res Commun 2000;278:440–6
   PubMed Web of Science ®Google Scholar
• Park YJ, Liu G, Tsuruta Y, et al. Participation of the urokinase receptor in neutrophil efferocytosis. Blood 2009;114:860–70
   PubMed Web of Science ®Google Scholar
• Gao W, Wang Z, Bai X, et al. Detection of soluble urokinase receptor by immunoradiometric assay and its application in tumor patients. Thromb Res 2001;102:25–31
   PubMed Web of Science ®Google Scholar
• Stephens RW, Pedersen AN, Nielsen HJ, et al. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 1997;43:1868–76
   PubMed Web of Science ®Google Scholar
• Rønne E, Behrendt N, Ploug M, et al. Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay. J Immunol Methods 1994;167:91–101
   PubMed Web of Science ®Google Scholar
• Zhou X, Xu M, Huang H, et al. An ELISA method detecting the active form of suPAR. Talanta 2016;160:205–10
   PubMed Web of Science ®Google Scholar
• Schlöndorff D. Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS? Kidney Int 2014;85:499–501
   PubMed Web of Science ®Google Scholar
• Riisbro R, Christensen IJ, Høgdall C, et al. Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. Int J Biol Markers 2001;16:233–9
   PubMed Web of Science ®Google Scholar
• Eugen-Olsen J, Andersen O, Linneberg A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 2010;268:296–308
   PubMed Web of Science ®Google Scholar
• Eugen-Olsen J, Ladelund S, Sørensen LT. Plasma suPAR is lowered by smoking cessation: a randomized controlled study. Eur J Clin Invest 2016;46:305–11
   PubMed Web of Science ®Google Scholar
• Tuomi H, Kultti J, Danielsson J, et al. Serum soluble urokinase plasminogen activator receptor in alcoholics: relation to liver disease severity, fibrogenesis, and alcohol use. J Gastroenterol Hepatol 2014;29:1991–5
   PubMed Web of Science ®Google Scholar
• Gustafsson A, Ajeti V, Ljunggren L. Detection of suPAR in the saliva of healthy young adults: comparison with plasma levels. Biomark Insights 2011;6:119–25
   PubMedGoogle Scholar
• Kurtipek E, Kesli R, Bekçik TT, et al. Assessment of soluble urokinase-type plasminogen activator receptor (suPAR) in chronic obstructive pulmonary disease. Int Arch Med 2015;8:1–7
   Google Scholar
• Can Ü, Güzelant A, Yerlikaya FH, Yosunkaya Ş. The role of serum soluble urokinase-type plasminogen activator receptor in stable chronic obstructive pulmonary disease. J Investig Med 2014;62:938–43
   PubMed Web of Science ®Google Scholar
• Gumus A, Altintas N, Cinarka H, et al. Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD. Int J Chron Obstruct Pulmon Dis 2015;10:357–65
   PubMed Web of Science ®Google Scholar
• Ivancsó I, Toldi G, Bohács A, et al. Relationship of circulating soluble urokinase plasminogen activator receptor (suPAR) levels to disease control in asthma and asthmatic pregnancy. PLoS One 2013;8:e60697
   PubMed Web of Science ®Google Scholar
• Tunc T, Cekmez F, Yildirim S, et al. Predictive value of soluble urokinase plasminogen activator receptor, soluble ST2, and IL-33 in bronchopulmonary dysplasia. Pediatr Res 2014;75:788–92
   PubMed Web of Science ®Google Scholar
• Geboers DG, de Beer FM, Tuip-de Boer AM, et al. Plasma suPAR as a prognostic biological marker for ICU mortality in ARDS patients. Intensive Care Med 2015;41:1281–90
   PubMed Web of Science ®Google Scholar
• Backes Y, van der Sluijs KF, Tuip de Boer AM, et al. Soluble urokinase-type plasminogen activator receptor levels in patients with burn injuries and inhalation trauma requiring mechanical ventilation: an observational cohort study. Crit Care 2011;15:R270
   PubMed Web of Science ®Google Scholar
• Zimmermann HW, Koch A, Seidler S, et al. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver Int 2012;32:500–9
   PubMed Web of Science ®Google Scholar
• Ostrowski SR, Piironen T, Hoyer-Hansen G. al. High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005;39:23–31
   PubMed Web of Science ®Google Scholar
• Ostrowski SR, Plomgaard P, Fischer CP, et al. Interleukin-6 infusion during human endotoxaemia inhibits in vitro release of the urokinase receptor from peripheral blood mononuclear cells. Scand J Immunol 2005;61:197–206
   PubMed Web of Science ®Google Scholar
• Higazi AA, El-Haj M, Melhem A, et al. Immunomodulatory effects of plasminogen activators on hepatic fibrogenesis. Clin Exp Immunol 2008;152:163–73
   PubMed Web of Science ®Google Scholar
• Shanmukhappa K, Sabla GE, Degen JL, Bezerra JA. Urokinase-type plasminogen activator supports liver repair independent of its cellular receptor. BMC Gastroenterol 2006;6:40
   PubMed Web of Science ®Google Scholar
• Sevgi DY, Bayraktar B, Gündüz A, et al. Serum soluble urokinase-type plasminogen activator receptor and interferon-γ-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B. Wien Klin Wochenschr 2016;128:28–33
   PubMed Web of Science ®Google Scholar
• Berres ML, Schlosser B, Berg T, et al. Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection. J Clin Gastroenterol 2012;46:334–8
   PubMed Web of Science ®Google Scholar
• Zimmermann HW, Reuken PA, Koch A, et al. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality. J Intern Med 2013;274:86–100
   PubMed Web of Science ®Google Scholar
• Sjöwall C, Martinsson K, Cardell K, et al. Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease. Transl Res 2015;165:658–66
   PubMed Web of Science ®Google Scholar
• Lönnkvist MH, Theodorsson E, Holst M, et al. Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy. Scand J Gastroenterol 2011;46:420–7
   PubMed Web of Science ®Google Scholar
• Blasi F, Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 2010;584:1923–30
   PubMed Web of Science ®Google Scholar
• Kolho KL, Valtonen E, Rintamäki H, Savilahti E. Soluble urokinase plasminogen activator receptor suPAR as a marker for inflammation in pediatric inflammatory bowel disease. Scand J Gastroenterol 2012;47:951–5
   PubMed Web of Science ®Google Scholar
• Borné Y, Persson M, Melander O, et al. Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation. Eur J Heart Fail 2014;16:377–83
   PubMed Web of Science ®Google Scholar
• Intzilakis T, Hartmann G, Mouridsen MR, et al. Soluble urokinase plasminogen activator receptor, C-reactive protein and triglyceride are associated with heart rate variability in non-diabetic Danes. Eur J Clin Invest 2013;43:457–68
   PubMed Web of Science ®Google Scholar
• Jalkanen V, Vaahersalo J, Pettilä V, et al. The predictive value of soluble urokinase plasminogen activator receptor (SuPAR) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study. Resuscitation 2014;85:1562–7
   PubMed Web of Science ®Google Scholar
• Rundgren M, Lyngbaek S, Fisker H, Friberg H. The inflammatory marker suPAR after cardiac arrest. Ther Hypothermia Temp Manag 2015;5:89–94
   PubMed Web of Science ®Google Scholar
• Lyngbæk S, Andersson C, Marott JL, et al. Soluble urokinase plasminogen activator receptor for risk prediction in patients admitted with acute chest pain. Clin Chem 2013;59:1621–9
   PubMed Web of Science ®Google Scholar
• Lyngbæk S, Marott JL, Møller DV, et al. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention. Am J Cardiol 2012;110:1756–63
   PubMed Web of Science ®Google Scholar
• Rasmussen L, Knudsen A, Katzenstein TL, et al. Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardialinfarction in HIV-1-infected patients: a nested case-control study. HIV Med 2016;17:350–7
   PubMed Web of Science ®Google Scholar
• Mekonnen G, Corban MT, Hung OY, et al. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease. Atherosclerosis 2015;239:55–60
   PubMed Web of Science ®Google Scholar
• Eapen DJ, Manocha P, Ghasemzadeh N, et al. Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events. J Am Heart Assoc 2014;3:e001118. Erratum in: J Am Heart Assoc 2015;4:e000563
   PubMed Web of Science ®Google Scholar
• Sørensen MH, Gerke O, Eugen-Olsen J, et al. Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects. Atherosclerosis 2014;237:60–6
   PubMed Web of Science ®Google Scholar
• Persson M, Östling G, Smith G, et al. Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease. Stroke 2014;45:18–23
   PubMed Web of Science ®Google Scholar
• Schutte AE, Myburgh A, Olsen MH, et al. Exploring soluble urokinase plasminogen activator receptor and its relationship with arterial stiffness in a bi-ethnic population: the SAfrEIC-study. Thromb Res 2012;130:273–7
   PubMed Web of Science ®Google Scholar
• Olson FJ, Thurison T, Ryndel M, et al. Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability. Clin Biochem 2010;43:124–30
   PubMed Web of Science ®Google Scholar
• Lyngbæk S, Marott JL, Sehestedt T, et al. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score. Int J Cardiol 2013;167:2904–11
   PubMed Web of Science ®Google Scholar
• Sehestedt T, Lyngbæk S, Eugen-Olsen J, et al. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. Atherosclerosis 2011;216:237–43
   PubMed Web of Science ®Google Scholar
• Botha S, Fourie CM, Schutte R, et al. 1C.01: Soluble urokinase plasminogen activator receptor as. J Hypertens 2015;33:e9
   PubMedGoogle Scholar
• Botha S, Fourie CM, Schutte R, et al. Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population. Int J Cardiol 2015;184:631–6
   PubMed Web of Science ®Google Scholar
• Botha S, Fourie CM, Schutte R, et al. Associations of suPAR with lifestyle and cardiometabolic risk factors. Eur J Clin Invest 2014;44:619–26
   PubMed Web of Science ®Google Scholar
• Lyngbæk S, Sehestedt T, Marott JL, et al. CRP and suPAR are differently related to anthropometry and subclinical organ damage. Int J Cardiol 2013;167:781–5
   PubMed Web of Science ®Google Scholar
• du Plooy CS, Kruger R, Huisman HW, et al. Extracellular matrix biomarker, fibulin-1 and its association with soluble uPAR in a bi-ethnic South African population: the SAfrEIC study. Heart Lung Circ 2015;24:298–305
   PubMed Web of Science ®Google Scholar
• Kruger R, Rasmussen LM, Argraves WS, et al. Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study). PLoS One 2014;9:e101522
   PubMed Web of Science ®Google Scholar
• Meijers B, Poesen R, Claes K, et al. Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. Kidney Int 2015;87:210–16
   PubMed Web of Science ®Google Scholar
• Pawlak K, Pawlak D, Mysliwiec M. Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients. Thromb Res 2007;120:871–6
   PubMed Web of Science ®Google Scholar
• Pawlak K, Mysliwiec M, Pawlak D. The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients. Thromb Res 2008;122:328–35
   PubMed Web of Science ®Google Scholar
• Botha S, Fourie CM, Schutte R, et al. Soluble urokinase plasminogen activator receptor and hypertension among black South Africans after 5 years. Hypertens Res 2015;38:439–44
   PubMed Web of Science ®Google Scholar
• Slot O, Brünner N, Locht H, et al. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis 1999;58:488–92
   PubMed Web of Science ®Google Scholar
• Cerinic MM, Generini S, Partsch G, et al. Synoviocytes from osteoarthritis and rheumatoid arthritis produce plasminogen activators and plasminogen activator inhibitor-1 and display u-PA receptors on their surface. Life Sci 1998;63:441–53
   PubMed Web of Science ®Google Scholar
• Pliyev BK, Menshikov MY. Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis. Inflammation 2010;33:1–9
   PubMed Web of Science ®Google Scholar
• Toldi G, Bekő G, Kádár G, et al. Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission. Clin Chem Lab Med 2013;51:327–32
   PubMed Web of Science ®Google Scholar
• Enocsson H, Wetterö J, Skogh T, Sjöwall C. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus. Transl Res 2013;162:287–96
   PubMed Web of Science ®Google Scholar
• Qin DD, Song D, Huang J, et al. Plasma-soluble urokinase-type plasminogen activator receptor levels are associated with clinical and pathological activities in lupus nephritis: a large cohort study from China. Lupus 2015;24:546–57
   PubMed Web of Science ®Google Scholar
• Soltysiak J, Zachwieja J, Benedyk A, et al. Circulating suPAR as a biomarker of disease severity in children with proteinuric glomerulonephritis. Minerva Pediatr 2016. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Reuning U, Bang NU. Regulation of the urokinase-type plasminogen activator receptor on vascular smooth muscle cells is under the control of thrombin and other mitogens. Arterioscler Thromb 1992;12:1161–70
   PubMed Web of Science ®Google Scholar
• Pepper MS, Sappino AP, Stocklin R, et al. Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol 1993;122:673–84
   PubMed Web of Science ®Google Scholar
• Koolwijk P, van Erck MG, de Vree WJ, et al. Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol 1996;132:1177–88
   PubMed Web of Science ®Google Scholar
• Lund LR, Ellis V, Ronne E, et al. Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549. Biochem J 1995;310:345–52
   PubMed Web of Science ®Google Scholar
• Yoshida E, Tsuchiya K, Sugiki M, et al. Modulation of the receptor for urokinase-type plasminogen activator in macrophage-like U937 cells by inflammatory mediators. Inflammation 1996;20:319–26
   PubMed Web of Science ®Google Scholar
• Florquin S, van den Berg JG, Olszyna DP, et al. Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int 2001;59:2054–61
   PubMed Web of Science ®Google Scholar
• Cubellis MV, Wun TC, Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. Embo J 1990;9:1079–85
   PubMed Web of Science ®Google Scholar
• Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997;9:714–24
   PubMed Web of Science ®Google Scholar
• Wei Y, Lukashev M, Simon DI, et al. Regulation of integrin function by the urokinase receptor. Science 1996;273:1551–5
   PubMed Web of Science ®Google Scholar
• Xue W, Mizukami I, Todd RF, III et al. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res 1997;57:1682–9
   PubMed Web of Science ®Google Scholar
• Pliyev BK. Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87). Mol Cell Biochem 2009;321:111–22
   PubMed Web of Science ®Google Scholar
• Toldi G, Szalay B, Bekő G, et al. Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in ankylosing spondylitis. Joint Bone Spine 2013;80:96–8
   PubMed Web of Science ®Google Scholar
• Kurtipek GS, Kesli R, Akyurek FT, et al. Plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in Behçet's disease and correlation with disease activity. Int J Rheum Dis 2016. [Epub ahead of print]. doi:10.1111/1756-185X.12873
   Web of Science ®Google Scholar
• Manetti M, Rosa I, Milia AF, et al. Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma? Ann Rheum Dis 2014;73:1700–9
   PubMed Web of Science ®Google Scholar
• Legány N, Toldi G, Distler JH, et al. Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis. Clin Chem Lab Med 2015;53:1799–805
   PubMed Web of Science ®Google Scholar
• Wu CZ, Chang LC, Lin YF, et al. Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy. Clin Biochem 2015;48:1324–9
   PubMed Web of Science ®Google Scholar
• Heraclides A, Jensen TM, Rasmussen SS, et al. The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body weight status. Diabetologia 2013;56:1542–6
   PubMed Web of Science ®Google Scholar
• Haugaard SB, Andersen O, Hansen TW, et al. The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men. Diabet Med 2012;29:479–87
   PubMed Web of Science ®Google Scholar
• Theilade S, Lyngbaek S, Hansen TW, et al. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes. J Intern Med 2015;277:362–71
   PubMed Web of Science ®Google Scholar
• Theilade S, Rossing P, Eugen-Olsen J, et al. suPAR level is associated with myocardial impairment assessed with advanced echocardiography in patients with type 1 diabetes with normal ejection fraction and without known heart disease or end-stage renal disease. Eur J Endocrinol 2016;174:745–53
   PubMed Web of Science ®Google Scholar
• Hayek SS, Sever S, Ko YA, et al. Soluble urokinase receptor and chronic kidney disease. N Engl J Med 2015;373:1916–25
   PubMed Web of Science ®Google Scholar
• Almroth G, Lönn J, Uhlin F, et al. Fibroblast growth factor 23, hepatocyte growth factor, interleukin-6, high-sensitivity C-reactive protein and soluble urokinase plasminogen activator receptor. Inflammation markers in chronic haemodialysis patients? Scand J Immunol 2013;78:285–90
   PubMed Web of Science ®Google Scholar
• Pawlak K, Ulazka B, Mysliwiec M, et al. Vascular endothelial growth factor and uPA/suPAR system in early and advanced chronic kidney disease patients: a new link between angiogenesis and hyperfibrinolysis? Transl Res 2012;160:346–54
   PubMed Web of Science ®Google Scholar
• Pawlak K, Buraczewska-Buczko A, Mysliwiec M, et al. Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment. Am J Med Sci 2010;339:5–9
   PubMed Web of Science ®Google Scholar
• Pawlak K, Pawlak D, Mysliwiec M. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity. Thromb Res 2007;119:475–80
   PubMed Web of Science ®Google Scholar
• Guo SM, Han M, Chen MX, et al. Soluble urokinase receptor levels are correlated with focal segmental glomerulosclerosis lesions in IgA nephropathy: a cohort study from China. PLoS One 2015;10:e0138718
   PubMed Web of Science ®Google Scholar
• Zhao Y, Liu L, Huang J, et al. Plasma soluble urokinase receptor level is correlated with podocytes damage in patients with IgA nephropathy. PLoS One 2015;10:e0132869
   Web of Science ®Google Scholar
• Cathelin D, Placier S, Ploug M, et al. Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice. J Am Soc Nephrol 2014;25:1662–8
   PubMed Web of Science ®Google Scholar
• Wei C, Möller CC, Altintas MM, et al. Modification of kidney barrier function by the urokinase receptor. Nat Med 2008;14:55–63
   PubMed Web of Science ®Google Scholar
• Maas RJ, Deegens JK, Wetzels JF. Serum suPAR in patients with FSGS: trash or treasure? Pediatr Nephrol 2013;28:1041–8
   PubMed Web of Science ®Google Scholar
• Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011;17:952–60
   PubMed Web of Science ®Google Scholar
• Kronbichler A, Saleem MA, Meijers B, et al. Soluble urokinase receptors in focal segmental glomerulosclerosis: a review on the scientific point of view. J Immunol Res 2016;2016:2068691
   PubMed Web of Science ®Google Scholar
• Spinale JM, Mariani LH, Kapoor S, et al. A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease. Kidney Int 2015;87:564–74
   PubMed Web of Science ®Google Scholar
• Sinha A, Bajpai J, Saini S, et al. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children. Kidney Int 2014;85:649–58
   PubMed Web of Science ®Google Scholar
• Franco Palacios CR, Lieske JC, Wadei HM, et al. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation 2013;96:394–9
   PubMed Web of Science ®Google Scholar
• Huang J, Liu G, Zhang YM, et al. Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int 2013;84:366–72
   PubMed Web of Science ®Google Scholar
• Jin J, Li YW, He Q. Primary and recurrent focal segmental glomerulosclerosis closely link to serum soluble urokinase-type plasminogen activator receptor levels. Transplant Proc 2015;47:1760–5
   PubMed Web of Science ®Google Scholar
• Chen JS, Chang LC, Wu CZ, et al. Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models. J Biomed Sci 2016;23:24
   PubMed Web of Science ®Google Scholar
• Wei C, Trachtman H, Li J, et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 2012;23:2051–9
   PubMed Web of Science ®Google Scholar
• Li F, Zheng C, Zhong Y, et al. Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS. Clin J Am Soc Nephrol 2014;9:1903–11
   PubMed Web of Science ®Google Scholar
• Peng Z, Mao J, Chen X, et al. Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children. Pediatr Nephrol 2015;30:301–7
   PubMed Web of Science ®Google Scholar
• Harita Y, Ishizuka K, Tanego A, et al. Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis. Pediatr Nephrol 2014;29:1553–60
   PubMed Web of Science ®Google Scholar
• Huang J, Liu G, Zhang YM, et al. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis. BMC Med 2014;12:81
   PubMed Web of Science ®Google Scholar
• Cara-Fuentes G, Wei C, Segarra A, et al. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance. Pediatr Nephrol 2014;29:1363–71
   PubMed Web of Science ®Google Scholar
• Wada T, Nangaku M, Maruyama S, et al. A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease. Kidney Int 2014;85:641–8
   PubMed Web of Science ®Google Scholar
• Staeck O, Slowinski T, Lieker I, et al. Recurrent primary focal segmental glomerulosclerosis managed with intensified plasma exchange and concomitant monitoring of soluble urokinase-type plasminogen activator receptor-mediated podocyte β3-integrin activation. Transplantation 2015;99:2593–7
   PubMed Web of Science ®Google Scholar
• Alachkar N, Wei C, Arend LJ, et al. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy. Transplantation 2013;96:649–56
   PubMed Web of Science ®Google Scholar
• Ma J, Zhang B, Liu S, et al. 1,25-dihydroxyvitamin D(3) inhibits podocyte uPAR expression and reduces proteinuria. PLoS One 2013;8:e64912
   PubMed Web of Science ®Google Scholar
• Zhang B, Xie S, Shi W, et al. Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria. Nephrol Dial Transplant 2012;27:1746–55
   PubMed Web of Science ®Google Scholar
• Gellermann J, Schaefer F, Querfeld U. Serum suPAR levels are modulated by immunosuppressive therapy of minimal change nephrotic syndrome. Pediatr Nephrol 2014;29:2411–14
   PubMed Web of Science ®Google Scholar
• Backes Y, van der Sluijs KF, Mackie DP, et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med 2012;38:1418–28
   PubMed Web of Science ®Google Scholar
• Tsirigotis P, Chondropoulos S, Frantzeskaki F, et al. Thrombocytopenia in critically ill patients with severe sepsis/septic shock: Prognostic value and association with a distinct serum cytokine profile. J Crit Care 2016;32:9–15
   PubMed Web of Science ®Google Scholar
• Suberviola B, Castellanos-Ortega A, Ruiz Ruiz A, et al. Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission. Intensive Care Med 2013;39:1945–52
   PubMed Web of Science ®Google Scholar
• Jalkanen V, Yang R, Linko R, et al. SuPAR and PAI-1 in critically ill, mechanically ventilated patients. Intensive Care Med 2013;39:489–96
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Norrby-Teglund A, Mylona V, et al. Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor. Crit Care 2012;16:R149
   PubMedGoogle Scholar
• Uusitalo-Seppälä R, Huttunen R, Tarkka M, et al. Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study. J Intern Med 2012;272:247–56
   PubMed Web of Science ®Google Scholar
• Savva A, Raftogiannis M, Baziaka F, et al. Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis. J Infect 2011;63:344–50
   PubMed Web of Science ®Google Scholar
• Mölkänen T, Ruotsalainen E, Thorball CW, Järvinen A. Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2011;30:1417–24
   PubMed Web of Science ®Google Scholar
• Huttunen R, Syrjänen J, Vuento R, et al. Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 2011;270:32–40
   PubMed Web of Science ®Google Scholar
• Koch A, Voigt S, Kruschinski C, et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 2011;15:R63
   PubMed Web of Science ®Google Scholar
• Wittenhagen P, Kronborg G, Weis N, et al. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin Microbiol Infect 2004;10:409–15
   PubMed Web of Science ®Google Scholar
• El-Mekkawy MS, Saleh NY, Sonbol AA. Soluble urokinase plasminogen activator receptor: a new biomarker in the pediatric intensive care unit. Indian J Pediatr 2016;83:661–9
   PubMed Web of Science ®Google Scholar
• Okulu E, Arsan S, Akin IM, et al. Serum Levels of Soluble Urokinase Plasminogen Activator Receptor in Infants with Late-onset Sepsis. J Clin Lab Anal 2015;29:347–52
   PubMed Web of Science ®Google Scholar
• Şirinoğlu M, Soysal A, Karaaslan A, et al. The diagnostic value of soluble urokinase plasminogen activator receptor (suPAR) compared to C-reactive protein (CRP) and procalcitonin (PCT) in children with systemic inflammatory response syndrome (SIRS). J Infect Chemother 2016;23:17–22
   PubMedGoogle Scholar
• Siahanidou T, Margeli A, Tsirogianni C, et al. Clinical value of plasma soluble urokinase-type plasminogen activator receptor levels in term neonates with infection or sepsis: a prospective study. Mediators Inflamm 2014;2014:375702
   PubMed Web of Science ®Google Scholar
• Yilmaz G, Köksal I, Karahan SC, et al. The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in systemic inflammatory response syndrome. Clin Biochem 2011;44:1227–30
   PubMed Web of Science ®Google Scholar
• Kofoed K, Andersen O, Kronborg G, et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care 2007;11:R38
   PubMed Web of Science ®Google Scholar
• Casagranda I, Vendramin C, Callegari T, et al. Usefulness of suPAR in the risk stratification of patients with sepsis admitted to the emergency department. Intern Emerg Med 2015;10:725–30
   PubMed Web of Science ®Google Scholar